Study Progression on Non-small Cell Lung Cancer with EGFR Mutation
Treated by Immune Checkpoint Inhibitors.
10.3779/j.issn.1009-3419.2018.08.11
- Author:
Rilan BAI
1
;
Naifei CHEN
1
;
Jiuwei CUI
1
Author Information
1. Cancer Center, the First Hospital of Jilin University, Changchun 130021, China.
- Publication Type:Journal Article
- Keywords:
EGFR mutation;
Immune checkpoint inhibitors;
Lung neoplasms;
PD-L1
- MeSH:
Carcinoma, Non-Small-Cell Lung;
drug therapy;
genetics;
immunology;
ErbB Receptors;
genetics;
Humans;
Immune System;
drug effects;
immunology;
Lung Neoplasms;
drug therapy;
genetics;
immunology;
Molecular Targeted Therapy;
methods;
Mutation
- From:
Chinese Journal of Lung Cancer
2018;21(8):641-648
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, epidermal growth factor receptor tyrosine kinase inhibitors have been recommended by many guidelines as first-line drugs for advanced non-small cell lung cancer (NSCLC) with EGFR gene mutations and no resistance. However, with the prolongation of medication time, most appear acquired resistance. In recent years, breakthroughs in inhibitors of programmed death-1 (PD-1) and its ligand (PD1 ligand, PD-L1) have rapidly changed the therapeutic model of NSCLC. Recent studies have shown that the efficacy of immune checkpoint inhibitors in EGFR-mutant NSCLC patients is not satisfactory, which might be caused by low PD-L1 expression, inhibitory immune microenvironment and low tumor mutation load. This review will elaborate the immune microenvironment of NSCLC patients with EGFR mutation, the latest study progression of immune checkpoint inhibitors and its combined with TKI, expecting to bring new hopes for the treatment of EGFR-mutant NSCLC patients.
.
